Ivermectin (Tablet) interactions
Full monograph for Ivermectin (Tablet)Check it against another medicine
Medicines
84 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Abametapir | Moderate | Metabolism | Based on in vitro inhibition data, a single topical application of abametapir lotion may increase plasma concentrations of drugs that are substrates of CYP450… | 1 sources — open the full entry |
| Apalutamide | Moderate | Absorption · Metabolism | Coadministration with apalutamide may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4, 2C9, 2C19, breast… | 5 sources — open the full entry |
| Aprepitant | Moderate | Metabolism | Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4… | 2 sources — open the full entry |
| Asciminib | Moderate | Metabolism | Coadministration with asciminib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is… | 1 sources — open the full entry |
| Beclomethasone Dipropionate + Chloramphenicol + Clotrimazole + Lidocaine | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ivermectin and the risk of adverse effects. The proposed mechanism… | 4 sources — open the full entry |
| Bosentan Monohydrate | Moderate | Metabolism | Coadministration with bosentan may decrease the plasma concentrations of drugs that are substrates of the CYP450 2C9 and/or 3A4 isoenzymes. The mechanism is… | 5 sources — open the full entry |
| Brigatinib | Moderate | Metabolism | Coadministration with brigatinib may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. Brigatinib has been shown in… | 6 sources — open the full entry |
| Chloramphenicol (Oral) | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ivermectin and the risk of adverse effects. The proposed mechanism… | 4 sources — open the full entry |
| Chloramphenicol + Lidocaine Hydrochloride | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ivermectin and the risk of adverse effects. The proposed mechanism… | 4 sources — open the full entry |
| Clarithromycin | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ivermectin and the risk of adverse effects. The proposed mechanism… | 4 sources — open the full entry |
| Dasatinib | Moderate | Metabolism | Coadministration with dasatinib may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. The mechanism is decreased clearance due to… | 8 sources — open the full entry |
| Deferasirox | Moderate | Metabolism | Coadministration with deferasirox may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism may involve… | 3 sources — open the full entry |
| Dexamethasone + Chloramphenicol | Moderate | Metabolism · Unknown | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ivermectin and the risk of adverse effects. The proposed mechanism…2 documented mechanisms | 4 sources — open the full entry |
| Efavirenz | Moderate | Metabolism | Coadministration with efavirenz may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is accelerated… | 2 sources — open the full entry |
| Elacestrant | Moderate | Absorption | Coadministration with elacestrant may increase the plasma concentrations of drugs that are substrates of P-glycoprotein (P-gp) and/or breast cancer resistance… | 1 sources — open the full entry |
| Enzalutamide | Moderate | Metabolism | Coadministration with enzalutamide may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, 2C9, 2C19, and/or P-glycoprotein (P-gp)… | 4 sources — open the full entry |
| ErythromycinLotionOral | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ivermectin and the risk of adverse effects. The proposed mechanism… | 4 sources — open the full entry |
| Esomeprazole + Amoxicillin + Clarithromycin | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ivermectin and the risk of adverse effects. The proposed mechanism… | 4 sources — open the full entry |
| Ethanol + Isopropyl alcohol | Moderate | Others | Alcohol may increase the plasma concentrations of ivermectin. The mechanism of interaction is unknown. | 2 sources — open the full entry |
| Itraconazole | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ivermectin and the risk of adverse effects. The proposed mechanism… | 4 sources — open the full entry |
| Ketoconazole | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ivermectin and the risk of adverse effects. The proposed mechanism… | 4 sources — open the full entry |
| Ketoconazole + Zinc Pyrithione + Aleovera | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ivermectin and the risk of adverse effects. The proposed mechanism… | 4 sources — open the full entry |
| Lamivudine + Zidovudine + Nevirapine | Moderate | Metabolism | Coadministration with nevirapine may decrease the plasma concentrations and therapeutic efficacy of drugs that are substrates of CYP450 3A4. The proposed… | 4 sources — open the full entry |
| Lansoprazole + Amoxicillin + Clarithromycin | Moderate | Metabolism · Unknown | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ivermectin and the risk of adverse effects. The proposed mechanism…2 documented mechanisms | 4 sources — open the full entry |
| Lapatinib | Moderate | Metabolism | Coadministration with lapatinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2C8 isoenzyme, CYP450 3A4 isoenzyme, and/or… | 6 sources — open the full entry |
| Larotrectinib | Moderate | Metabolism | Coadministration with larotrectinib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. | 4 sources — open the full entry |
| Lefamulin Acetate | Moderate | Metabolism | When administered orally, lefamulin may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. Based on interaction with… | 6 sources — open the full entry |
| Lopinavir + Ritonavir | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ivermectin and the risk of adverse effects. The proposed mechanism… | 4 sources — open the full entry |
| Lorlatinib | Moderate | Metabolism | Coadministration with lorlatinib may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The proposed mechanism is… | 3 sources — open the full entry |
| Mavacamten | Moderate | Metabolism | Coadministration with mavacamten may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4, 2C9, and/or 2C19. The proposed… | 1 sources — open the full entry |
| Mifepristone | Moderate | Metabolism | Based on in vitro inhibition data, coadministration with mifepristone may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4… | 10 sources — open the full entry |
| Mifepristone + Misoprostol | Moderate | Metabolism | Based on in vitro inhibition data, coadministration with mifepristone may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4… | 10 sources — open the full entry |
| Nelfinavir | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ivermectin and the risk of adverse effects. The proposed mechanism… | 4 sources — open the full entry |
| Nilotinib | Moderate | Metabolism | Based on in vitro inhibition data, coadministration with nilotinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein… | 6 sources — open the full entry |
| Nirmatrelvir + Ritonavir | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ivermectin and the risk of adverse effects. The proposed mechanism… | 4 sources — open the full entry |
| Oxcarbazepine | Moderate | Metabolism | Coadministration with oxcarbazepine may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is… | 9 sources — open the full entry |
| Posaconazole | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ivermectin and the risk of adverse effects. The proposed mechanism… | 4 sources — open the full entry |
| Rabeprazole + Amoxicillin + Clarithromycin | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ivermectin and the risk of adverse effects. The proposed mechanism… | 4 sources — open the full entry |
| Ribociclib | Moderate | Metabolism | Coadministration with ribociclib may increase the plasma concentrations and pharmacologic effects of drugs that are substrates of CYP450 3A4. The proposed… | 10 sources — open the full entry |
| Selpercatinib | Moderate | Metabolism | Coadministration with selpercatinib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism… | 6 sources — open the full entry |
| Somatropin | Moderate | Metabolism | Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4. | 4 sources — open the full entry |
| Sotorasib | Moderate | Metabolism | Coadministration with sotorasib may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The proposed mechanism is… | 2 sources — open the full entry |
| Tacrolimus MonohydrateOralTopical | Moderate | Metabolism | Coadministration of sirolimus or tacrolimus with other drugs that are also metabolized by CYP450 3A4 may result in elevated plasma concentrations of the… | 7 sources — open the full entry |
| Tea tree oil + Echinacea + Geothermal water | Moderate | Metabolism | Coadministration with echinacea may alter the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4. Echinacea appears to… | 2 sources — open the full entry |
| Tucatinib | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ivermectin and the risk of adverse effects. The proposed mechanism… | 4 sources — open the full entry |
| Vonoprazan + Amoxicillin + Clarithromycin | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ivermectin and the risk of adverse effects. The proposed mechanism… | 4 sources — open the full entry |
| Voriconazole | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ivermectin and the risk of adverse effects. The proposed mechanism… | 4 sources — open the full entry |
| Warfarin Sodium | Moderate | Others | Coadministration of warfarin with ivermectin has been associated with rare, postmarketing reports of increased INR (International Normalized Ratio). The… | 38 sources — open the full entry |
| Armodafinil | Minor | Metabolism | Coadministration with modafinil (the racemate) or armodafinil (the R-enantiomer) may decrease the plasma concentrations of drugs that are substrates of the… | 11 sources — open the full entry |
Food & lifestyle
alcohol
ModerateOthers
Alcohol may increase the plasma concentrations of ivermectin. The mechanism of interaction is unknown.
What to do: Patients receiving ivermectin therapy should preferably avoid the consumption of alcohol to prevent any undue adverse effects of ivermectin.
2 sources
- Chijioke CP, Okonkwo PO "Adverse events following mass ivermectin therapy for onchocerciasis." Trans R Soc Trop Med Hyg 86 (1992): 284-6
- Pollak PT, Slayter KL "Reduced serum theophylline concentrations after discontinuation of azithromycin: evidence for an unusual interaction." Pharmacotherapy 17 (1997): 827-9